Biomedical Engineering Reference
In-Depth Information
77. Wettwer E, Hala O, Christ T et al (2004) Role of IKur in controlling action potential shape
and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation
110:2299-2306
78. Knobloch K, Brendel J, Peukert S et al (2002) Electrophysiological and antiarrhythmic
effects of the novel IKur channel blockers, S9947 and S20951, on left vs. right pig atrium
in vivo in comparison with the IKr blockers dofetilide, azimilide, dl-sotalol and ibutilide.
Naunyn-Schmiedebergs Arch Pharmacol 366:482-487
79. Bachmann A, Gutcher I, Kopp K et al (2001) Characterization of a novel Kv1.5 channel
blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes. Naunyn
Schmiedebergs Arch Pharmacol 364:472-478
80. Nattel S, Zeng FD (1984) Frequency-dependent effects of antiarrhythmic drugs on action
potential duration and refractoriness of canine cardiac Purkinje fibers. J Pharmacol Exp Ther
229:283-291
81. Peukert S, Brendel J, Pirard B et al (2004) Pharmacophore-based search, synthesis, and
biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg
Med Chem Lett 14:2823-2827
82. Lloyd DG, Buenemann CL, Todorov NP et al (2004) Scaffold hopping in de novo design.
Ligand generation in the absence of receptor information. J Med Chem 47:493-496
83. Brendel J, Boehme T, Peukert S et al (2002) Preparation of anthranilic acid amides as
antiarrhythmics, WO 2002100825, Aventis Pharma Deutschland G.m.b.H., Germany, p 102
84. Rezazadeh S, Claydon TW, Fedida D (2006) KN-93 (2-[N-(2-hydroxyethyl)]-N-(4-methoxy
benzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmod-
ulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated
potassium channels. J Pharmacol Exp Ther 317:292-299
85. Nanda KK, Nolt MB, Cato MJ et al (2006) Potent antagonists of the Kv1.5 potassium
channel: synthesis and evaluation of analogous N, N-diisopropyl-2-(pyridine-3-yl)
acetamides. Bioorg Med Chem Lett 16:5897-5901
86. Trotter WB, Nanda KK, Wolkenberg S et al (2007) Heteroaryl compounds, processes for
preparing them, pharmaceutical compositions containing them, and their use as potassium
channel inhibitors, WO 2007050348, Merck & Co., Inc., USA, p 100
87. Wolkenberg S, Bilodeau MT, Nolt MB (2007) Preparation of (arylpyridinyl)dipyridiny-
lethanol derivatives as potassium channel inhibitors, WO 2007050347, Merck & Co., Inc.,
USA, p 31
88. Trotter BW, Nanda KK, Wolkenberg SE et al (2007) Substituted butanamide derivatives as
potassium channel inhibitors and their preparation, pharmaceutical compositions, and use in
the treatment of cardiac arrhythmias and related diseases, WO 2007015775. Merck & Co.,
Inc., USA, p 65
89. Beshore DC, Liverton NJ, McIntyre CJ et al (2010) Discovery of triarylethanolamine
inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett 20:2493-2496
90. Vaccaro W, Huynh T, Lloyd J et al (2008) Dihydropyrazolopyrimidine inhibitors of Kv1.5
(IKur). Bioorg Med Chem Lett 18:6381-6385
91. Lloyd J, Finlay HJ, Atwal K et al (2009) Dihydropyrazolopyrimidines containing
benzimidazoles as Kv1.5 potassium channel antagonists. Bioorg Med Chem Lett 19:
5469-5473
92. Lloyd J, Finlay HJ, Vacarro W et al (2010) Pyrrolidine amides of pyrazolodihydropyr-
imidines as potent and selective Kv1.5 blockers. Bioorg Med Chem Lett 20:1436-1439
93. Yang Q, Du L, Tsai K-C et al (2009) Pharmacophore Mapping for Kv1.5 Potassium Channel
Blockers. QSAR Comb Sci 28:59-71
94. Orth PM, Hesketh JC, Mak CK et al (2006) RSD1235 blocks late INa and suppresses early
afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res
70:486-496
95. Fedida D, Orth PM, Chen JY et al (2005) The mechanism of atrial antiarrhythmic action of
RSD1235. J Cardiovasc Electrophysiol 16:1227-1238
